Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The study will be conducted in asthmatic children aged 5 to 11 years and is based on a
single-dose, open-label, randomized, 2-way cross-over design where a Dry Powder Inhaler (DPI)
fixed combination of beclometasone dipropionate (BDP) 35 μg plus formoterol fumarate (FF) 4
μg is compared with the free combination of licensed BDP DPI and FF DPI